$CLYM News

HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target

Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies

Why Is Climb Bio Stock Gaining Friday?

Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price Target

BTIG Maintains Buy on Climb Bio, Raises Price Target to $20

Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune Thrombocytopenia

Guggenheim Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $35

BTIG Reiterates Buy on Climb Bio, Maintains $19 Price Target

Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series

Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026

HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate

BTIG Maintains Buy on Climb Bio, Raises Price Target to $19

Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE

Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing

Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026